QIAGEN logo

Syndromic testing – empowering clinical diagnostics

The value of syndromic multiplex testing for infectious disease diagnostics

The value of syndromic multiplex testing for infectious disease diagnostics

Patients with infectious illnesses frequently have signs and symptoms that are indicative of a disease but that are not unique enough to clinically distinguish what pathogen is making them ill.

Patients can present with general, non-specific symptoms such as cough, myalgia and headache. The lack of a clear diagnosis results in broad treatment, extensive monitoring and possibly unnecessary interventions.

With syndromic testing, results for multiple pathogens are delivered at once. And compared to traditional methods, it can provide results faster. The benefits of syndromic testing extend through the lab, hospital and to the patients.

Sign up for our next webinar

Sign up for our next webinar

Join Dr. Josep Pareja for an interactive webinar on the value of syndromic testing for infectious disease diagnostics.

Date and time: Tuesday, June 22, 13:00 CET/14:00 Helsinki time

Title: Benefits of syndromic testing in infectious disease diagnostics – QIAstat-Dx test results in clinical decision making

Speaker: Dr. Josep Pareja, Director Medical Affairs, QIAGEN

Register for the webinar

Deliver comprehensive diagnostic results with QIAstat-Dx

A patient may have the flu. A cold. Or they may have been exposed to COVID-19. How can you get results that patients need faster? The QIAstat-Dx Respiratory SARS-CoV-2 Panel gets you results for 21 respiratory targets, including SARS-CoV-2, in about an hour.

Clinical value of syndromic testing in the COVID-19 pandemic and beyond

Clinical value of syndromic testing in the COVID-19 pandemic and beyond

Before the COVID-19 pandemic, the majority of respiratory illnesses were caused by the seasonal circulation of common pathogens, including influenza virus. Given the uncertainty surrounding respiratory infections in the future, rapid detection and differential of respiratory viruses through syndromic testing will be essential. Read a piece from our medical affairs team on the future of syndromic testing beyond COVID-19.

Read the article in Finnish here